Laboratorios Haymann

What Laboratorios Haymann does

Laboratorios Haymann S.A. is a privately held Uruguayan pharmaceutical company headquartered in Montevideo that manufactures, represents, and distributes pharmaceutical and health products across multiple therapeutic categories. Founded in 1960 (per firmographic records; company-stated history references 1970) and operating with 51-100 employees, the company has built a multi-vertical portfolio spanning respiratory (13+ products for asthma, COPD, and allergies), gastroenterology (6 products), vascular health (Hemoxan), probiotics (Biótica line with 4 products using proprietary 4th-generation double-layer capsule technology), sweeteners (Tevias, Sucralight, Aspartil), natural sedatives (Calmasilán), smoking cessation (Nicogom), and the recently launched CBD pharmaceutical Xannadiol. The company holds proprietary formulation IP including the BIO-SUPPORT technology platform and ACELU gluten-free certification for applicable product lines.

The business model is a hybrid B2B2C pharmaceutical and consumer health manufacturer-distributor. Revenue is generated through the sale of branded prescription and OTC products to Uruguayan pharmacies and healthcare providers, with direct customer engagement via a dedicated contact center (0800 3000). Manufacturing is conducted in a Montevideo facility that is US FDA-approved and WHO GMP-compliant, with IFPMA promotional ethics compliance, indicating both domestic manufacturing and capability for international/export distribution. The combination of regulatory certifications, proprietary formulation technology, and a 50+ year operating history constitutes the core operational moat. There is no disclosed equity funding, investor base, or financial performance data; the company is private and self-sustaining on available evidence.

The recent strategic posture (2026) is offensive: securing FDA plant approval and WHO GMP certification positions the company for potential export and contract manufacturing, while product launches in CBD (Xannadiol) and probiotic technology (Biótica) expand the addressable consumer health surface. The Fumador Cero social responsibility program paired with the Nicogom line indicates a willingness to combine commercial and public-health positioning. Customer concentration appears structurally low given the pharmacy-channel long-tail distribution model across diverse therapeutic categories, with no named enterprise or anchor customer dependency identified.

Name

Laboratorios Haymann

Legal name

Laboratorios Haymann S.A.

Website

https://haymann.com.uy

Company type

Private

Founded year

1970

Operating status

Operating

Headcount range

51–100 employees

Short description

Laboratorios Haymann is a Uruguayan pharmaceutical manufacturer headquartered in Montevideo that produces, distributes, and represents branded respiratory, gastroenterology, vascular, probiotic, sweetener, sedative, smoking cessation, and CBD products through pharmacy and healthcare channels, with a recently FDA-approved manufacturing facility.

Ownership category

akta.pro rank

Product category

Pharmaceutical Manufacturing

NAICS

Pharmaceutical Preparation Manufacturing (325412), Medicinal and Botanical Manufacturing (325411), Drugs and Druggists' Sundries Merchant Wholesalers (42421)

SIC

Pharmaceutical Preparations (2834), Medicinal Chemicals & Botanical Products (2833)

akta.pro primary industry

Pulmonology & Allergy Specialty Pharmaceuticals (HLAIACAF)

akta.pro secondary industries

Gastroenterology & Hepatology Pharmaceuticals (HLAIAAAI), Nicotine Replacement Therapy (NRT) Consumer Products Manufacturing & Brands (CRADAJAJ), Cold, Flu, Cough & Allergy Remedies (Decongestants, Antihistamines, Cough Syrups, Lozenges) (CRADAMAD)

Keywords

• Pharmaceutical manufacturing
• Respiratory medications
• Probiotic supplements
• Pharmaceutical distribution
• Stevia sweeteners

Headquarters

HQ city

Montevideo

HQ country

Uruguay

HQ region

Latin America

Offices1 record

Markets served

GTM type

B2C

Offering type

Hardware or Manufacturing

Cost components

Personnel, Operations, Supply Chain, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

1. Pharmaceutical product sales: Sale of branded pharmaceutical and health products including respiratory medications, probiotics, sweeteners, gastrointestinal products, natural sedatives, vascular health products, and smoking cessation aids. Products sold through pharmacies and medical distribution channels in Uruguay.
2. CBD pharmaceutical products: Xannadiol (cannabidiol-based medication) sold for treatment of seizures associated with Lennox-Gastaut syndrome, Dravet syndrome, and tuberous sclerosis complex. Sold in 5% and 10% concentrations.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels5 records

Core offering

Laboratorios Haymann S.A. is a Uruguayan pharmaceutical company that manufactures, represents, commercializes, and distributes branded pharmaceutical and health products. Its portfolio spans respiratory medications (inhalers for asthma and COPD), gastroenterology products, vascular health medications, CBD-based epilepsy treatments (Xannadiol), probiotic supplements (Biótica line), natural sweeteners (Tevias, Sucralight, Aspartil), natural sedatives (Calmasilán), and nicotine replacement therapy (Nicogom). Products are sold through pharmacies across Uruguay under WHO GMP-certified manufacturing standards with US FDA plant approval.

Product overview

Laboratorios Haymann is a Uruguayan pharmaceutical company with over 50 years of experience manufacturing, representing, and distributing health products. The company operates across multiple product lines: a Respiratory Line (Línea Respiratoria) featuring 13 branded inhalers and medications (Aeronid, Axana, Bilamin, Budenair, Estraplus, Estravent, Furamyst, Histacetin, Inhalplús, Montelair, Serflú, Ventiplús, Ventoxiplús) for asthma, COPD, and allergies; a Gastroenterology Line (Línea Gastroenterológica) with 6 products (Espasmosilan, Salazodin, Silan variants) for digestive disorders; a Vascular Health product (Hemoxan) for venous circulation; Biótica Probiotic supplements (Pro, Cran, S3, Pro Vital) for gut and immune health; three sweetener brands (Tevias stevia-based, Sucralight sucralose-based, Aspartil aspartame-based); Calmasilán natural sedative; Nicogom nicotine gum for smoking cessation; and Xannadiol cannabinoid-based medication for epilepsy syndromes. The portfolio covers pharmaceutical medications, nutraceuticals, and consumer health products across respiratory, digestive, cardiovascular, and wellness categories.

Differentiator

Problem solved

Functional benefit

Brands

• Biótica: Probiotic product line including Biótica Pro, Biótica Cran, Biótica S3, and Biótica Pro Vital.
• Xannadiol
• Tevias
• Sucralight
• Aspartil
• Aeronid
• Axana
• Budenair
• Serflú
• Ventiplús
• Ventoxiplús
• Estraplús
• Estravent
• Furamyst
• Inhalplús
• Montelair
• Silan
• Salazodin
• Espasmosilan
• Hemoxan
• Calmasilán
• Nicogom
• Bilamin
• Histacetin

Products and services

• Xannadiol (Cannabidiol CBD Solution)
• Biótica Probiotic Line (Pro, Cran, S3, Pro Vital)
• Respiratory Medication Line (Aeronid, Axana, Bilamin, Budenair, Estraplus, Estravent, Furamyst, Histacetin, Inhalplús, Montelair, Serflú, Ventiplús, Ventoxiplús)
• Gastroenterology Medication Line (Silan, Salazodin, Espasmosilan)
• Hemoxan
• Calmasilán
• Nicogom
• Tevias
• Sucralight
• Aspartil

Segments3 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

One partnership is on record.

• ACELU (Asociación de Celíacos del Uruguay)minorOthersACELU provides gluten-free certification for Laboratorios Haymann's sweetener products (Tevias, Sucralight, Aspartil), validating that products are safe for consumers with celiac disease.

Scale indicators2 records

Recent moves6 records

Expansion highlights10 records

Direct peers

• Laboratorios Celsius: Domestic Uruguayan pharmaceutical company offering branded Rx and OTC products distributed through the same pharmacy channel as Laboratorios Haymann.
• Laboratorios Clausen: Uruguayan pharmaceutical manufacturer competing in similar therapeutic categories within the same domestic market, with comparable scale and distribution model.
• Urufarma: Uruguayan generic and branded pharmaceutical manufacturer with overlapping therapeutic categories and shared distribution through local pharmacies.

Regional players

• Eurofarma: Brazilian pharmaceutical manufacturer with a multi-category branded generics and specialty portfolio across Latin America — comparable scale and diversification strategy.
• Gador: Argentine pharmaceutical manufacturer with a similar diversified branded generics and specialty pharma portfolio across Latin America.
• Roemmers: Leading Argentine pharmaceutical manufacturer with a broadly diversified branded portfolio across respiratory, GI, cardiovascular, and consumer health — comparable business model at larger regional scale.
• Laboratorios Bagó: Argentina-headquartered pharmaceutical group with Latin American operations across multiple therapeutic areas, directly comparable diversified pharma manufacturing model.

Emerging players

• Genomma Lab Internacional: Latin American OTC pharmaceutical and personal care company with a similar multi-category branded consumer health model including OTC, probiotics, and wellness SKUs.

Broad incumbents

• AstraZeneca: Global respiratory leader (Symbicort, Fasenra) competing head-to-head with Haymann's inhaler portfolio across asthma, COPD, and allergic rhinitis categories.
• GSK: Global pharmaceutical company whose respiratory franchise (Advair/Seretide, Trelegy) competes with Haymann's Aeronid and Serflú combination inhalers in the Uruguayan market.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks7 records

Key highlights7 records

Customer concentration

• Facebookfacebook.com/FumadorCero
• LinkedInlinkedin.com/company/haymann

Compliance3 records

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Laboratorios Haymann